Drug intelligence / Profile preview

anti-MUC1* C2

Development stage: Preclinical
Lead developer: Minerva Biotechnologies
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

anti-MUC1* C2 is a preclinical-stage therapeutic program being developed by Minerva Biotechnologies. It targets MUC1*, the cleaved, oncogenic form of the MUC1 transmembrane protein that is expressed on a wide variety of solid tumors. The program explores two distinct modalities: bispecific antibodies (BsAbs), designed to recruit and activate effector cells against MUC1*-expressing cancer cells, and antibody-drug conjugates (ADCs), which utilize the anti-MUC1* antibody to deliver cytotoxic payloads directly to the tumor site.

Other names: Anti MUC1* C2 - BsAbs or ADCs

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on anti-MUC1* C2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-MUC1* C2.

Explore the full profile